What SOOIL Developments does

SOOIL Developments Co., Ltd. is a privately held South Korean medical device company founded in 1978 that specializes in insulin pump therapy for diabetes management. Its product portfolio is anchored by the Diabecare DANA-i, an insulin pump capable of delivering precise micro-doses of insulin with integrated blood glucose measurement, and the DANA Diabecare IIS, which adds exercise mode, temporary pause, and time-segmented meal bolus configuration. The hardware line is complemented by the AnyDANA/DANA Mobile App (Android, available on Google Play), disposable infusion sets, syringes, and the SOOIL Mall e-commerce platform; the company also distributes the CamAPS FX closed-loop artificial pancreas system.

The underlying technology combines subcutaneous insulin infusion mechanics with Bluetooth-enabled smartphone connectivity, and the DANA-RS has received the highest security grade from the German Federal Office for Information Security (BSI), with the broader DANA line holding IoT security certification in the medical device category. SOOIL sells primarily through three channels: its SOOIL Mall direct-to-consumer e-commerce platform (operated by wholly-owned subsidiary DanaMed), a network of international distributors, and SOOIL USA, a wholly-owned subsidiary in San Diego that handles direct US sales and customer support. Pricing is not publicly disclosed and customers must contact the company or purchase through the mall.

The company serves individual diabetes patients requiring intensive insulin therapy as its primary segment, with healthcare professionals serving as a secondary channel through training and clinical support resources. The recurring revenue base comes from the combination of pump hardware sales and the proprietary consumables (infusion sets, syringes, accessories) that are required for ongoing use, creating an annuity-style stream tied to the active pump install base. SOOIL maintains active engagement with the global diabetes research community, with participation in major conferences (ADA, EASD, ATTD, ICDM, Arab Health) and validation of its technology through research published in the New England Journal of Medicine.

Name

SOOIL Developments

Legal name

SOOIL Developments Co., Ltd

Website

https://sooil.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

SOOIL Developments is a privately held South Korean medical device company that designs, manufactures, and sells DANA-branded insulin pumps, related consumables, and smartphone apps for diabetes patients, distributing via its SOOIL Mall e-commerce platform, international distributors, and a US subsidiary.

Ownership category

akta.pro rank

Product category

Insulin Pump Therapy / Diabetes Management Devices

SIC

Pumps & Pumping Equipment (3561)

akta.pro primary industry

Insulin Pumps (Tubed) (HLAHAHAB)

akta.pro secondary industries

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Insulin Pumps & Patch Pumps (HLAHAIAG), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)

Keywords

• Insulin pump therapy
• Diabetes management devices
• Continuous subcutaneous infusion
• Medical device manufacturing
• Blood glucose monitoring

Headquarters

HQ city

Giheung

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Insulin Pumps: Sale of insulin pump devices including Diabecare DANA-i, DANA Diabecare IIS, and previous models
2. Infusion Sets: Sale of infusion sets for insulin pump therapy
3. Accessories: Sale of accessories for insulin pumps and diabetes management
4. Blood Glucose Management Products: Sale of blood glucose monitoring and management products

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

SOOIL Developments manufactures and sells insulin pump systems and related consumables for diabetes management. Its core products include the Diabecare DANA-i insulin pump with blood glucose measurement and micro-dose delivery, the DANA Diabecare IIS pump with exercise and meal-bolus controls, infusion sets, syringes, and companion mobile applications, sold primarily to diabetes patients through its own e-commerce platform and international distributors.

Product overview

SOOIL Developments offers a portfolio of insulin pump products led by the Diabecare DANA-i (flagship model with integrated blood glucose monitoring) and DANA Diabecare IIS (with exercise mode and configurable settings). The product line is complemented by the AnyDANA/DANA Mobile App for Android smartphones (available on Google Play Store), infusion sets, and the DANA-3cc-Syringe. The company also operates SOOIL Mall, its e-commerce platform for product sales. The portfolio is unified around subcutaneous insulin infusion therapy for diabetes management, with over 47 years of innovation in insulin pump therapy.

Differentiator

Problem solved

Functional benefit

Brands

• Diabecare: Product line of insulin pumps including DANA-i and DANA Diabecare IIS models
• DANA
• SOOIL Mall
• AnyDANA

Products and services

• Diabecare DANA-i Flagship insulin pump capable of delivering precise micro-doses of insulin into the body with integrated blood glucose measurement functionality, designed for diabetes patients requiring continuous subcutaneous insulin infusion.
• DANA Diabecare IIS Insulin pump featuring exercise mode, temporary pause function, and the ability to set different meal bolus amounts by time period, designed for diabetes patients who want configurable insulin delivery.
• Infusion Sets Disposable infusion sets used with DANA insulin pumps for continuous subcutaneous insulin delivery therapy, sold as recurring consumables to diabetes patients.
• DANA-3cc-Syringe 3cc syringe component used for insulin delivery within the DANA insulin pump system.
• SOOIL Mall Direct e-commerce platform selling insulin pumps, infusion sets, accessories, blood glucose management products, and the DANA mobile app to diabetes patients in South Korea.

Quantifiable outcome

• DANA insulin pump effectiveness validated in published research in the New England Journal of Medicine (NEJM)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global diabetes leader offering the MiniMed 780G AID system and pumps integrated with its own CGM. Direct competitor in insulin pump therapy across SOOIL's markets, but at vastly larger scale.
• Roche Diabetes Care: Historically relevant insulin delivery / BGM player; adjacent competitor in diabetes management with broad portfolio and global distribution comparable to SOOIL's go-to-market scope.

Direct peers

• Tandem Diabetes Care: Specialist insulin pump maker (t:slim X2 with Control-IQ AID). Closest direct competitor in tubed connected pumps with smartphone control, targeting the same Type 1 diabetes patient profile as SOOIL DANA-i.
• Insulet Corporation: Maker of the Omnipod tubeless patch pump, now with Omnipod 5 AID. Competes directly for the same T1D patient population and is structurally reshaping pump form-factor expectations versus SOOIL's tubed architecture.
• Ypsomed: Swiss insulin pump manufacturer (mylife Loop / YpsoPump) with strong EMEA presence and proprietary AID. Direct competitor in European markets where SOOIL also distributes.

Emerging players

• CamDiab: Developer of the CamAPS FX closed-loop algorithm used with DANA pumps. SOOIL's existing AID partner and therefore a tightly coupled commercial peer in the closed-loop ecosystem.
• Diabeloop: European AID algorithm company integrating with multiple pump hardware partners. Competes with CamAPS FX in the algorithmic layer that sits atop SOOIL and rival pumps.
• Beta Bionics: Developer of the iLet bionic pancreas, an AID system using its own dedicated pump hardware. Emerging direct competitor in the automated insulin delivery category SOOIL is pursuing via CamAPS FX.

Others

• Dexcom: Leading continuous glucose monitor (CGM) maker whose sensors integrate with most modern insulin pumps including AID systems. Strategic ecosystem partner/dependency for SOOIL's closed-loop ambitions.
• Abbott Diabetes Care: Major CGM (FreeStyle Libre) and diabetes care player. Strategic ecosystem context for SOOIL: CGM-pump integration is increasingly required for AID, making Abbott a key partner/competitor dynamic in the broader diabetes stack.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOOIL Developments